On July 13, Alnylam Pharmaceuticals fell 5.29% in regular trading, trading at $281.53 USD/share, with Turnover of $117 million.
Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, individual stocks showed mixed performance. Among individual stocks, Agenus up 139.67%, Q32 Bio Inc. up 65.39%, Moderna up 0.06%, Nuvalent up 0.04%, AbbVie down 0.82%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)